Krystal Biotech receives FDA approval for innovative gene therapy drug

Krystal Biotech Inc. announced that the U.S. Food and Drug Administration approved the use of VYJUVEK to treat dystrophic epidermolysis bullosa (DEB) for patients who are six months of age or older.

Source: bizjournals.com Health Care:Physician Practices headlines - May 19, 2023 Category: American Health Authors: Nate Doughty Source Type: news